OVERVIEW The history of the Cancer Center's Clinical Science Division is rooted in the eariiest years of the Cancer Center. It began with the partnership of Dana-Farber Cancer Institute (DFCI) and Children's Hospital Boston (CHB), which was established in the late 1940s. The fomiation of the DF/HCC consortium has resulted in the development of a new scientific environment that fosters a high degree of inter-institutional collaboration among clinical investigators and with basic and population colleagues. It also has provided invaluable access to a far greater patient base so that promising clinical trials can be conducted in a reasonable timeframe. The result has been an enriched and cohesive scientific community unified through a commitment to translational research and supported by a single clinical tiials structure. Organization The basic organizing unit for stimulating clinical research remains the Clinical Programs. The Clinical Science Division includes ten programs that are disease-focused (e.g.. Prostate Cancer) and one that supports translational pharmacology and early phase trials (TPETT). Cutaneous Oncology and Melanoma is a new Clinical Program in this application. It has had an excellent record of translational discovery, strong multiinstitutional leadership, a favorable record of innovative trials, a renewed SPORE and active membership.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA006516-47S2
Application #
8533072
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-05-15
Project End
2016-11-30
Budget Start
2012-05-15
Budget End
2012-11-30
Support Year
47
Fiscal Year
2012
Total Cost
$75,000
Indirect Cost
$32,143
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Kwee, Brian J; Budina, Erica; Najibi, Alexander J et al. (2018) CD4 T-cells regulate angiogenesis and myogenesis. Biomaterials 178:109-121
Madsen, Thomas; Braun, Danielle; Peng, Gang et al. (2018) Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol 42:528-538
Chen, Jingjing; Guccini, Ilaria; Di Mitri, Diletta et al. (2018) Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet 50:219-228
Li, Andrew G; Murphy, Elizabeth C; Culhane, Aedin C et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation. Proc Natl Acad Sci U S A 115:E9600-E9609
McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25
Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233
Kamareddine, Layla; Wong, Adam C N; Vanhove, Audrey S et al. (2018) Activation of Vibrio cholerae quorum sensing promotes survival of an arthropod host. Nat Microbiol 3:243-252
Schilit, Samantha L P; Morton, Cynthia C (2018) 3C-PCR: a novel proximity ligation-based approach to phase chromosomal rearrangement breakpoints with distal allelic variants. Hum Genet 137:55-62
Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296

Showing the most recent 10 out of 411 publications